| 1 | from concept to commercialization | | | | | | | 3 | 0.93% |
| 2 | operations from concept to | | | | | | | 2 | 0.62% |
| 3 | new destination for integrated | | | | | | | 2 | 0.62% |
| 4 | rd newsecondimages touchstone | | | | | | | 1 | 0.31% |
| 5 | newsecondimages touchstone a | | | | | | | 1 | 0.31% |
| 6 | newsecondimages touchstone a premier | | | | | | | 1 | 0.31% |
| 7 | lifesciences rd newsecondimages | | | | | | | 1 | 0.31% |
| 8 | nexus to nurture breakthroughs | | | | | | | 1 | 0.31% |
| 9 | research district the perfect | | | | | | | 1 | 0.31% |
| 10 | nurture breakthroughs across the | | | | | | | 1 | 0.31% |
| 11 | breakthroughs across the lifesciences | | | | | | | 1 | 0.31% |
| 12 | across the lifesciences value | | | | | | | 1 | 0.31% |
| 13 | the lifesciences value chain | | | | | | | 1 | 0.31% |
| 14 | newimagescorrected navi mumbai research | | | | | | | 1 | 0.31% |
| 15 | navi mumbai research district | | | | | | | 1 | 0.31% |
| 16 | mumbai research district the | | | | | | | 1 | 0.31% |
| 17 | to nurture breakthroughs across | | | | | | | 1 | 0.31% |
| 18 | facility in the heart | | | | | | | 1 | 0.31% |
| 19 | lifesciences facility in the | | | | | | | 1 | 0.31% |
| 20 | in the heart of | | | | | | | 1 | 0.31% |
| 21 | the heart of india’s | | | | | | | 1 | 0.31% |
| 22 | heart of india’s foremost | | | | | | | 1 | 0.31% |
| 23 | pharmaceutical hub locations hyderabad | | | | | | | 1 | 0.31% |
| 24 | hub locations hyderabad bengaluru | | | | | | | 1 | 0.31% |
| 25 | locations hyderabad bengaluru mumbai | | | | | | | 1 | 0.31% |
| 26 | hyderabad bengaluru mumbai not | | | | | | | 1 | 0.31% |
| 27 | bengaluru mumbai not just | | | | | | | 1 | 0.31% |
| 28 | mumbai not just brick | | | | | | | 1 | 0.31% |
| 29 | and mortar a thriving | | | | | | | 1 | 0.31% |
| 30 | mortar a thriving ecosystem | | | | | | | 1 | 0.31% |
| 31 | a thriving ecosystem of | | | | | | | 1 | 0.31% |
| 32 | thriving ecosystem of innovation | | | | | | | 1 | 0.31% |
| 33 | cuttingedge lifesciences rd | | | | | | | 1 | 0.31% |
| 34 | research 1gv an epicentre | | | | | | | 1 | 0.31% |
| 35 | 1gv an epicentre for | | | | | | | 1 | 0.31% |
| 36 | and gene therapies arx | | | | | | | 1 | 0.31% |
| 37 | concept to commercialization bhub | | | | | | | 1 | 0.31% |
| 38 | to commercialization bhub an | | | | | | | 1 | 0.31% |
| 39 | commercialization bhub an accelerator | | | | | | | 1 | 0.31% |
| 40 | bhub an accelerator that | | | | | | | 1 | 0.31% |